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Introduction
============

Coronary heart disease (CHD) remains the largest cause of death in Scotland, as elsewhere in Europe, the United States, and Australasia. Scotland has one of the highest CHD mortality rates in western Europe, accounting for more than 8000 deaths in 2009. Furthermore, CHD is a major cause of premature mortality (aged \<75 years). The burden of disease is substantial, and the estimated annual cost to the National Health Service (NHS) in Scotland exceeds £3bn (€3.7bn; \$5bn).[@ref1] CHD rates have fallen dramatically since the 1970s; age adjusted mortality rates for men dropped from 460 per 100 000 in 1979 to 136 per 100 000 in 2010, and rates for women dropped from 208 to 64 per 100 000.[@ref2] Studies in the United Kingdom, Europe, United States, and New Zealand have suggested that 45-75% of the substantial falls in deaths from CHD can be attributed to population-wide decreases in major risk factors such as smoking, blood pressure, and cholesterol.[@ref3] [@ref4] [@ref5] [@ref6] [@ref7] The remaining 25-55% can apparently be explained by use of cardiological treatments such as thrombolysis, aspirin, angiotensin converting enzyme inhibitors, statins, and coronary artery bypass graft surgery.[@ref8]

In Scotland, and elsewhere, evidence shows strong and persistent socioeconomic inequalities in CHD incidence and mortality.[@ref9] [@ref10] O'Flaherty et al reported that premature mortality was up to five times higher in the most deprived fifth compared with the most affluent. Worryingly, mortality trends in younger men and women seemed to have flattened recently, particularly in the two most deprived fifths.[@ref9] The IMPACT model has been developed to help to explain the decline in CHD deaths by quantifying the contributions of temporal changes in exposure to risk factors and uptake of treatments.[@ref11] The model has been previously validated and used to explain such falls in mortality in more than 20 countries including Scotland, New Zealand, Finland, England, and the United States.[@ref3] [@ref4] [@ref5] [@ref6] [@ref7] Since 2009, the model has been further developed as IMPACT~SEC~. This permits quantification of trends in CHD mortality, treatment uptakes, and risk factors in socioeconomic fifths.[@ref12]

Recent socioeconomic trends in many cardiovascular risk factors in Scotland have been unfavourable. For example, between 1995 and 2008 relative inequalities in blood pressure levels persisted while inequalities in the prevalence of smoking and diabetes increased in both men and women.[@ref13] What effect such trends have had on socioeconomic trends in CHD mortality is unclear.

Against this background, we aimed to quantify the decline in CHD mortality between 2000 and 2010 in Scotland and then use the IMPACT~SEC~ model to apportion this mortality decline to treatments and changes in risk factors across socioeconomic fifths.

Methods
=======

IMPACT~SEC~ model
-----------------

The IMPACT CHD mortality model is an epidemiological model originally developed to explore the contribution of modern cardiovascular treatment and changes in risk factors to the decline in CHD mortality in Scotland between 1975 and 1994.[@ref3] [@ref4] This deterministic, cell based model integrates data from many sources on patient numbers, treatment uptake, treatment effectiveness, risk factor trends, and consequent mortality effects. Using this information, the deaths prevented or postponed between two specified time points can be calculated. The proportion of the decline in CHD mortality over a certain time period can then be attributed to changes in risk factors and to specific treatments.

The model considers a comprehensive range of risk factors, CHD categories, and treatments. In brief, the model includes the population risk factors smoking, cholesterol, blood pressure, obesity, diabetes, and physical activity. It also includes nine mutually exclusive groups of patients: ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, secondary prevention after myocardial infarction, secondary prevention after revascularisation, chronic stable coronary artery disease, patients with severe heart failure requiring at least one admission to hospital, heart failure patients treated only in the community, and two primary pharmacological prevention groups of patients receiving antihypertensive drugs or statins.

The model has been further developed to partition into fifths the socioeconomic components concealed within the overall decline in CHD mortality and within the specific contributions of improved treatments and changes in population risk factors. The IMPACT~SEC~ model can be used to synthesise data by fifths of area deprivation from a range of databases (including population, mortality, case fatality, health surveys, hospital admissions, hospital prescribing, and community prescribing). The flexibility of the IMPACT~SEC~ model also allowed stratification of results by sex; however, we did no formal tests to explore possible disparities by sex. Further details for the IMPACT and the IMPACT~SEC~ models are described below and in the summary appendix and technical appendix, as well as in previous publications.[@ref11] [@ref12]

Data sources
------------

We sourced data relating to the Scottish population. We investigated all possible sources and selected the most up to date and representative dataset. Population estimates and CHD death counts (ICD10 (international classification of diseases, 10th revision) codes I10-I25) for 2000 and for 2010 by 10 year age bands (25-34 to ≥85 years), sex, and deprivation fifth came from National Records of Scotland ([www.nrscotland.gov.uk/](http://www.nrscotland.gov.uk/)). Emergency admissions and surgical interventions for acute myocardial infarction and unstable angina, as well as admissions for heart failure, came from the linked Scottish Morbidity Record (SMR01) and death record dataset provided by Information Services Division Scotland ([www.isdscotland.org/](http://www.isdscotland.org/)). Primary Care Clinical Informatics Unit, University of Aberdeen ([www.abdn.ac.uk/pcciu/index.htm](http://www.abdn.ac.uk/pcciu/index.htm)), provided information on treatment uptake in community based patients. Data on trends in risk factors came from the Scottish Health Surveys.[@ref14] [@ref15] [@ref16] [@ref17] Rehabilitation data came from Information Services Division Scotland. Treatment uptake data for heart failure in hospital came from the Healthcare Improvement Scotland audit ([www.healthcareimprovementscotland.org](http://www.healthcareimprovementscotland.org/)). We substituted English data from the Myocardial Ischaemia National Audit Project (MINAP) for uptake of acute coronary syndrome treatment in hospital.[@ref12] HeartStart (Scotland) provided community cardiopulmonary resuscitation data for ST elevation myocardial infarction patients.[@ref18]

Socioeconomic deprivation
-------------------------

We used the Scottish Index of Multiple Deprivation 2009v2 as a measure of area level deprivation.[@ref19] This identifies small concentrations of deprivation across Scotland by using data from various sources from around 2007-08. It is based on the stable and consistent small area geography called data zones, of which there are 6505 in Scotland (average population 798 (range 0-7061) people) ranked from most deprived (1) to least deprived (6505). The overall rankings are made up of seven individual domains: current income, employment, health, education, housing, access to services, and crime. On the basis of their postcode of residence, the data providers allocated patients treated in hospital or in the community to the corresponding deprivation fifth (to protect patients' anonymity). Survey respondents and deaths were matched to deprivation fifths in a similar manner. We could not obtain data from the Primary Care Clinical Informatics Unit stratified by people's Scottish Index of Multiple Deprivation area of residence. We therefore substituted this by using the 2001 Carstairs index of deprivation applied to the area of residence.[@ref20] This applied to patient numbers for chronic angina and heart failure in the community, as well as uptake of therapeutic drugs for all the community groups. We used a χ^2^ test for linear trend across deprivation fifths to assess socioeconomic gradients associated with the proportion of CHD deaths explained by the model.

Deaths prevented or postponed
-----------------------------

We calculated the number of CHD deaths expected in 2010 by indirect standardisation, multiplying the age, sex, and Scottish Index of Multiple Deprivation fifth specific mortality rates from CHD in 2000 by the relevant population counts for 2010. Summing over all strata then yielded the expected number of deaths. The difference between the number of expected and observed deaths then represented the fall in mortality, the total number of CHD deaths prevented or postponed to be explained by the combined changes in risk factor levels and treatment uptake between 2000 and 2010. If the model did not fully explain all deaths prevented or postponed in each fifth, we assumed any shortfalls to reflect unmeasured risk factors or imprecision in the model's parameters.

Mortality reductions attributable to treatment uptake
-----------------------------------------------------

We specified relevant treatments for each of the nine mutually exclusive patient groups. These included acute myocardial infarction (cardiopulmonary resuscitation, thrombolysis, angioplasty, aspirin, β blockers, and angiotensin converting enzyme inhibitors); secondary prevention following acute myocardial infarction and, separately, following coronary artery bypass graft surgery or angioplasty (aspirin, β blockers, angiotensin converting enzyme inhibitors, statins, warfarin, and rehabilitation); non-ST elevation myocardial infarction/acute coronary syndrome (aspirin, heparin, platelet glycoprotein IIB/IIIA inhibitors, and clopidogrel); chronic angina (coronary artery bypass graft surgery, angioplasty, aspirin, statins); and heart failure (angiotensin converting enzyme inhibitors, β blockers, spironolactone, aspirin, statins).

To avoid double counting of patients, we used linked individual data where possible; where this was not possible, we constructed distinct, non-overlapping CHD patient subgroups (see technical appendix). Numbers of patients eligible for each treatment, uptake of treatment, one year case fatality rates, and relative risk reduction due to treatment (all stratified by age, sex, patient subgroup, and deprivation fifth) came from relevant data sources as specified. As all treatments were in use in 2000, we calculated the net benefit of medical intervention in 2010 by subtracting the expected number of deaths prevented if the uptake rates in 2000 remained constant from the estimated number of deaths prevented calculated using the 2010 uptake rates (see technical appendix).

Mortality reductions attributable to risk factor changes
--------------------------------------------------------

We included six major cardiovascular risk factors in the model: the behavioural markers of smoking, physical inactivity, and body mass index and the physiological markers of systolic blood pressure, total serum cholesterol, and diagnosed diabetes. We calculated the absolute change in each risk factor between 2000 and 2010 by using generalised linear models with normal distribution and identity link for the continuous risk factors and generalised linear models with a binomial distribution and a logit link function for categorical variables (technical appendix, table C).

We estimated the mortality benefits of an absolute change in each risk factor between 2000 and 2010 by using a regression based approach for factors measured on a continuous scale (such as total blood cholesterol), using sex and age specific independent regression coefficients of mortality benefit for a unit change in mean risk factor obtained from published multivariate analyses (technical appendix, table I). For binary variables (such as smoking), we used a population attributable risk fraction approach using sex and age specific relative risks from the most recent meta-analyses and population cohort studies (technical appendix, table J). We jointly estimated mortality benefits of changes in risk factors by using the cumulative risk reduction approach, rather than simple addition (technical appendix, section 1.3).

We assumed that no further synergy existed between the treatment and risk factor components of the model. We assumed lag times between the change in cardiovascular risk factor levels and change in CHD mortality rates to be relatively rapid,[@ref21] so we did not specifically model them.

Uncertainty analysis
--------------------

We calculated 95% uncertainty intervals around the model output (that is, deaths prevented or postponed ) by using Monte Carlo simulation, much as in health economic evaluation studies.[@ref22] This calculation involved replacing all fixed input parameters used in the model by appropriate probability distributions and repeatedly recalculating the model output with values sampled from the defined input distributions. We used the Excel add-in Ersatz software ([www.epigear.com](http://www.epigear.com/)) to do 1000 runs to determine the 95% uncertainty intervals of the deaths prevented or postponed (2.5th and 97.5th centile values corresponding to the lower and upper limits) (see technical appendix).

Results
=======

The age standardised CHD mortality rate in adults aged 25 years and over fell by 43% between 2000 and 2010, from 262 to 148 deaths per 100 000 population (table 1[](#tbl1){ref-type="table"}). Mortality rates in 2000 in the most affluent fifth were 181 per 100 000 population compared with 349 per 100 000 in the most deprived fifth. Furthermore, the pace of fall differed significantly; the most affluent fifth decreased by 5.8% a year compared with 4.6% in the most deprived fifth. Thus absolute inequalities narrowed over the 10 year time period, whereas relative inequalities widened.

###### 

 Population, observed coronary heart disease deaths/age standardised rates for 2000 and 2010, and deaths prevented or postponed (DPPs) in Scotland stratified by deprivation fifths; data presented for whole population as well as by sex

                                                             Scotland           Scottish Index of Multiple Deprivation fifths                                                            
  ---------------------------------------------------------- ------------------ ----------------------------------------------- ------------------ ------------------ ------------------ ------------------
  **All adults aged ≥25 years**                                                                                                                                                          
  Population:                                                                                                                                                                            
   2000                                                      3 516 000          685 162                                         678 440            705 803            726 937            719 658
   2010                                                      3 685 544          735 789                                         761 624            755 559            736 790            695 782
  Observed deaths:                                                                                                                                                                       
   2000                                                      12 260             1553                                            1965               2563               2927               3252
   2010                                                      8042               1137                                            1417               1579               1920               1989
  Age standardised rates (per 100 000)\*:                                                                                                                                                
   2000 (95% CI)                                             262 (257 to 266)   181 (171 to 190)                                215 (206 to 225)   263 (253 to 274)   283 (272 to 293)   349 (337 to 361)
   2010 (95% CI)                                             148 (145 to 151)   100 (94 to 106)                                 120 (113 to 126)   137 (130 to 144)   177 (168 to 185)   217 (207 to 227)
  Annual % fall                                              5.5                5.8                                             5.7                6.3                4.6                4.6
  Expected deaths in 2010 (if 2000 rates had persisted)      13 813             2042                                            2476               2971               3107               3218
  Deaths prevented or postponed (expected−observed deaths)   5770               905                                             1060               1390               1185               1230
  DPPs as % of expected deaths†                              41.8               44.3                                            42.8               46.9               38.2               38.2
  **Men aged ≥25 years**                                                                                                                                                                 
  Age standardised rates (per 100 000)\*:                                                                                                                                                
   2000 (95% CI)                                             363 (354 to 372)   252 (235 to 270)                                293 (275 to 311)   364 (344 to 383)   393 (373 to 413)   494 (471 to 518)
   2010 (95% CI)                                             210 (204 to 216)   139 (128 to 150)                                169 (157 to 181)   197 (184 to 210)   253 (238 to 269)   313 (295 to 332)
  Annual % fall                                              5.3                5.8                                             5.4                5.9                4.3                4.5
  Expected deaths in 2010 (if 2000 rates had persisted)      7603               1119                                            1348               1653               1684               1799
  Deaths prevented or postponed (expected−observed deaths)   3075               495                                             565                745                605                665
  DPPs as % of expected deaths‡                              40.4               44.2                                            41.9               45.1               35.9               37.0
  **Women aged ≥25 years**                                                                                                                                                               
  Age standardised rates (per 100 000)\*:                                                                                                                                                
   2000 (95% CI)                                             185 (180 to 190)   129 (119 to 139)                                155 (145 to 166)   186 (175 to 197)   201 (190 to 213)   239 (226 to 252)
   2010 (95% CI)                                             99 (96 to 103)     69 (63 to 76)                                   81 (74 to 87)      91 (83 to 98)      118 (109 to 127)   141 (131 to 151)
  Annual % fall                                              6.0                6.0                                             6.3                6.9                5.2                5.1
  Expected deaths in 2010 (if 2000 rates had persisted)      6210               923                                             1128               1317               1423               1419
  Deaths prevented or postponed (expected−observed deaths)   2695               410                                             495                645                580                565
  DPPs as % of expected deaths§                              43.4               44.4                                            43.9               49.0               40.8               39.8

DPPs have been rounded to nearest 5.

\*Rates are standardised to European standard population aged ≥25 years by using direct standardisation.

†χ^2^ test for linear trend across deprivation fifths P\<0.0001.

‡χ^2^ test for linear trend across deprivation fifths P\<0.0001.

§χ^2^ test for linear trend across deprivation fifths P=0.002.

In total, 5770 fewer CHD deaths occurred in 2010 than would have been expected had the 2000 mortality rates persisted; this figure represents the total deaths prevented or postponed. One thousand two hundred and thirty deaths were prevented or postponed in the most deprived fifth, compared with 905 in the most affluent fifth (reflecting the higher initial burden of disease; table 1[](#tbl1){ref-type="table"}). When examining the deaths prevented or postponed as a percentage of expected deaths (percentage of deaths prevented or postponed), we observed a significant inequality gradient with a decrease in mortality of 44% in the most affluent fifth and 38% in the most deprived fifth; this gradient was also evident with stratification by sex.

As a result of improvements in the uptake of medical and surgical treatments, 2480 fewer deaths occurred. This accounted for 43% (95% confidence interval 33% to 61%) of the fall in total CHD mortality in Scotland (table 2[](#tbl2){ref-type="table"}); minimal difference existed in this proportion by sex (table 3[](#tbl3){ref-type="table"}). No significant socioeconomic gradient existed (46% in the most affluent fifth and 44% in the most deprived fifth), and this was true for each sex (table 3[](#tbl3){ref-type="table"}). Population level changes in risk factors accounted for approximately 2240 fewer deaths or 39% (29% to 49%) of the fall (table 4[](#tbl4){ref-type="table"}). These accounted for 36% of the deaths prevented or postponed in the most affluent fifth, increasing to 44% in the most deprived fifth. Again, minimal difference existed in these proportions by sex (table 3[](#tbl3){ref-type="table"}). The model could therefore explain only 82% of the overall fall in mortality (a shortfall of some 1055 deaths) (tables 3[](#tbl3){ref-type="table"} and 4[](#tbl4){ref-type="table"}). A socioeconomic gradient was evident; 81% of deaths prevented or postponed were explained in the most affluent fifth and 88% in the most deprived fifth.

###### 

 Coronary heart disease deaths prevented or postponed (DPPs) owing to changes in treatment uptake between 2000 and 2010 in Scotland, stratified by deprivation fifth

  Treatments by patient groups                           All    Proportion of total DPPs---% (95% uncertainty interval\*)   Scottish Index of Multiple Deprivation fifths                      
  ------------------------------------------------------ ------ ----------------------------------------------------------- ----------------------------------------------- ----- ------ ----- -----
  ST elevation myocardial infarction†:                   110    1.9 (0.6 to 5.0)                                            19                                              21    21     23    24
   Community cardiopulmonary resuscitation               2      0.0                                                         0                                               1     0      1     1
   Hospital cardiopulmonary resuscitation‡               0      0.0                                                         0                                               0     0      0     0
   Thrombolysis‡                                         0      0.0                                                         0                                               0     0      0     0
   Aspirin                                               4      0.1                                                         1                                               1     1      1     1
   β blockers                                            0      0.0                                                         0                                               0     0      0     0
   ACE inhibitors/ARB                                    0      0.0                                                         0                                               0     0      0     0
   Primary percutaneous coronary intervention            90     1.6                                                         16                                              18    18     19    19
   Coronary artery bypass graft surgery                  0      0.0                                                         0                                               0     0      0     0
   Clopidogrel                                           12     0.2                                                         2                                               2     2      3     2
  Non-ST elevation acute coronary syndrome†:             80     1.3 (0.7 to 2.4)                                            10                                              16    15     17    20
   Hospital cardiopulmonary resuscitation‡               0      0.0                                                         0                                               0     0      0     0
   Aspirin and heparin                                   40     0.7                                                         8                                               11    40     5     8
   Aspirin alone                                         0      0.0                                                         0                                               0     0      0     0
   Platelet glycoprotein IIB/IIIA inhibitors             −0.1   0.0                                                         0                                               0     −0.1   0     0
   Coronary artery bypass graft surgery                  0      0.0                                                         0                                               0     0      0     0
   Percutaneous coronary intervention                    7      0.1                                                         1                                               2     7      1     2
   ACE inhibitors/ARB                                    5      0.1                                                         1                                               1     5      1     1
   β blockers                                            3      0.0                                                         1                                               1     3      0     1
   Clopidogrel                                           23     0.4                                                         5                                               5     23     4     5
  Secondary prevention post-myocardial infarction†:      525    9.1 (7.4 to 11.2)                                           88                                              87    107    118   125
   Aspirin                                               35     0.6                                                         7                                               4     9      7     9
   β blockers                                            115    2.0                                                         19                                              19    21     27    29
   ACE inhibitors/ARB                                    154    2.7                                                         26                                              27    29     34    38
   Statins                                               169    2.9                                                         27                                              29    36     38    38
   Warfarin                                              12     0.2                                                         1                                               1     4      3     3
   Rehabilitation                                        39     0.7                                                         6                                               7     8      9     8
  Secondary prevention post-revascularisation†:          120    2.1 (1.4 to 3.0)                                            20                                              20    27     26    26
   Aspirin                                               −1     0.0                                                         0                                               −1    1      −1    1
   β blockers                                            29     0.5                                                         4                                               4     6      8     7
   ACE inhibitors/ARB                                    46     0.8                                                         8                                               7     11     10    9
   Statins                                               47     0.8                                                         7                                               9     11     10    10
   Warfarin                                              −4     −0.1                                                        0                                               0     −2     −2    −1
   Rehabilitation (coronary artery bypass graft)§        0.0    0.0                                                         0.0                                             0.0   0.0    0.0   0.0
   Rehabilitation (percutaneous coronary intervention)   1.8    0.0                                                         0.3                                             0.4   0.4    0.4   0.3
  Chronic stable coronary artery disease:                375    6.5 (4.6 to 9.1)                                            65                                              74    79     83    75
   Coronary artery bypass graft surgery                  −4     -0.1                                                        -3                                              1     0      0     −2
   Aspirin                                               43     0.8                                                         8                                               9     8      9     10
   Statins                                               226    3.9                                                         41                                              42    50     49    44
   ACE inhibitors                                        111    1.9                                                         19                                              23    21     25    23
  Heart failure in hospital†:                            85     1.5 (1.0 to 1.9)                                            12                                              13    18     19    23
   ACE inhibitors                                        22     0.4                                                         3                                               4     5      5     5
   β blockers                                            41     0.7                                                         6                                               7     9      10    10
   Spironolactone                                        18     0.3                                                         2                                               3     4      4     4
   Aspirin                                               4      0.1                                                         1                                               0     1      0     3
  Heart failure (community)†:                            265    4.6 (3.6 to 6.0)                                            29                                              39    58     65    76
   ACE inhibitors                                        35     0.6                                                         3                                               5     10     7     10
   β blockers                                            207    3.6                                                         24                                              29    42     47    65
   Spironolactone                                        21     0.4                                                         1                                               5     6      11    −2
   Aspirin                                               4      0.1                                                         1                                               −1    0      0     3
  Hypertension treatment†                                155    2.7 (0.7 to 6.0)                                            29                                              33    30     29    33
  Hyperlipidaemia treatment (statins)†                   770    13.3 (5.3 to 30.4)                                          140                                             170   183    138   138
  Total treatment†                                       2480   43.0 (33.0 to 61.3)                                         412                                             473   538    517   540

DPPs for Scotland (subtotals and total treatment only) have been rounded to nearest 5 (column 2).

ACE=angiotensin converting enzyme; ARB=angiotensin receptor blockers.

\*95% uncertainty interval corresponds to lower (2.5th centile) and upper (97.5th centile) limits of uncertainty analysis. These are shown to indicate range around central estimate of per cent of DPPs explained. Intervals are provided only for nine treatment patient groups.

†Subtotals (in rows) for coronary heart disease patient groups.

‡Assuming no change in thrombolysis and cardiopulmonary resuscitation uptake in community between 2000 and 2010; their contribution to DPPs have therefore been set to zero.

§No change in uptake between 2000 and 2010.

###### 

 Coronary heart disease deaths prevented or postponed (DPPs) as percentage of total DPPs to be explained, stratified by deprivation fifth; selected sex specific DPPs are provided

  Treatments by patient groups/risk factors         Scotland   Scottish Index of Multiple Deprivation fifths   P value\*                         
  ------------------------------------------------- ---------- ----------------------------------------------- ----------- ------ ------ ------- ----------
  **Treatments**                                                                                                                                 
  ST elevation myocardial infarction                1.9        2.1                                             2.0         1.5    1.9    2.0     0.96
  Non-ST elevation acute coronary syndrome          1.3        1.1                                             1.5         1.1    1.4    1.6     0.38
  Secondary prevention post-myocardial infarction   9.1        9.7                                             8.2         7.7    9.9    10.2    0.25
  Secondary prevention post-revascularisation       2.1        2.2                                             1.9         2.0    2.2    2.1     0.90
  Chronic stable coronary artery disease            6.5        7.2                                             7.0         5.7    7.0    6.1     0.40
  Heart failure in hospital                         1.5        1.3                                             1.3         1.3    1.6    1.9     0.22
  Heart failure in community                        4.6        3.2                                             3.7         4.2    5.5    6.2     0.0001
  Hypertension treatment                            2.7        3.2                                             3.1         2.1    2.5    2.7     0.32
  Hyperlipidaemia treatment (statins)               13.3       15.4                                            16.1        13.1   11.7   11.2    \<0.0001
  Total treatments---all†                           43.0       45.5                                            44.7        38.6   43.6   43.9    0.53
  Total treatments---men†                           44.8       46.0                                            43.3        40.6   50.7   44.6    0.43
  Total treatments---women†                         41.0       44.8                                            46.4        36.6   36.6   43.4    0.1
  **Risk factors**                                                                                                                               
  Smoking                                           3.6        1.5                                             2.3         3.0    4.5    6.1     \<0.0001
  Diabetes                                          −8.2       −5.3                                            −7.1        −7.1   −9.4   −11.5   \<0.0001
  Physical inactivity                               1.7        1.3                                             1.5         1.5    1.9    2.3     0.06
  Systolic blood pressure, mm Hg                    36.9       37.5                                            37.3        33.2   40.3   37.2    0.51
  Total cholesterol, mmol/L                         8.9        4.7                                             5.4         6.8    12.3   13.8    \<0.0001
  Body mass index                                   −4.1       −3.9                                            −4.1        −3.6   −4.5   −4.3    0.49
  Total risk factors†                               38.8       35.9                                            35.3        33.7   45.1   43.5    \<0.0001
  Total risk factors---men†                         39.5       37.5                                            38.4        34.8   44.3   42.7    0.01
  Total risk factors---women†                       37.9       33.8                                            31.8        32.4   45.9   44.6    \<0.0001
  **Deaths prevented or postponed**                                                                                                              
  DPPs explained by model---all†                    81.7       81.3                                            80.0        72.3   88.7   87.5    \<0.0001
  DPPs explained by model---men†                    84.3       83.6                                            81.7        75.4   95.1   87.3    \<0.0001
  DPPs explained by model---women†                  78.9       78.6                                            78.1        69.0   82.5   88.0    \<0.0001
  DPPs not explained by model†                      18.3       18.7                                            20.0        27.7   11.3   12.5    ---
  **DPP counts**                                                                                                                                 
  DPPs explained by model†‡:                        4720       736                                             847         1006   1053   1075    ---
   Due to treatment uptake‡                         2480       412                                             473         538    517    540     ---
   Due to risk factor change‡                       2240       325                                             374         469    535    535     ---
  DPPs unexplained by model†‡                       1055       169                                             212         385    134    154     ---
  Total DPPs†‡                                      5770       905                                             1060        1390   1185   1230    ---

\*χ^2^ test for linear trend.

†Subtotals (in rows).

‡Sex specific coronary heart disease DPPs as percentage of sex specific total DPPs to be explained (full sex stratified tables are available in technical appendix).

‡DPPs for Scotland (column 2) and total DPPs (last row) have been rounded to nearest 5.

###### 

 Coronary heart disease deaths prevented or postponed (DPPs) owing to changes in risk factor prevalence between 2000 and 2010 in Scotland stratified by deprivation fifth

  Risk factors                      Scotland   Proportion of total DPPs---% (95% uncertainty interval\*)   Scottish Index of Multiple Deprivation fifths                        
  --------------------------------- ---------- ----------------------------------------------------------- ----------------------------------------------- ------ ------ ------ ------
  Smoking                           210        3.6 (2.5 to 5.0)                                            14                                              25     41     53     75
  Diabetes                          −475       −8.2 (−11.1 to −5.9)                                        −48                                             −75    −99    −112   −141
  Physical inactivity               100        1.7 (1.5 to 2.4)                                            12                                              16     21     23     28
  Systolic blood pressure, mm Hg†   2130       36.9 (27.4 to 44.5)                                         340                                             394    461    479    457
  Total cholesterol, mmol/L‡        510        8.9 (4.0 to 13.7)                                           43                                              57     95     147    170
  Body mass index                   −235       −4.1 (−5.6 to −2.4)                                         −35                                             -44    −50    −54    −53
  Total risk factors                2240       38.8 (27.9 to 49.0)                                         325                                             374    469    535    535
  Total treatment§                  2480       43.0 (33.0 to 61.3)                                         412                                             473    538    517    540
  DPPs explained by model           4720       81.7 (64.7 to 98.8)                                         736                                             847    1006   1053   1075
  DPPS not explained                1055       ---                                                         169                                             212    385    134    154
  Total DPPs                        5770       ---                                                         905                                             1060   1390   1185   1230

DPPs for Scotland (column 2) and total DPPs (last row) have been rounded to nearest 5.

\*95% uncertainty interval corresponds to lower (2.5th centile) and upper (97.5th centile) limits of uncertainty analysis.

†After subtracting DPPs due to hypertension treatment in primary prevention.

‡After subtracting DPPs due to statin treatment in primary prevention.

§See table 2 for detailed breakdown by patient group and treatment type.

Increased treatments
--------------------

The largest contribution to deaths prevented by increased uptake of treatment came from statin treatment for hyperlipidaemia (approximately 13% of the total mortality reduction), followed by secondary prevention after myocardial infarction (9%) and management of chronic stable coronary artery disease (7%) (table 2[](#tbl2){ref-type="table"}). Uptake rates of statins and angiotensin converting enzyme inhibitors or angiotensin receptor blockers more than doubled between 2000 and 2010 for secondary prevention and the management of stable coronary artery disease (table 5[](#tbl5){ref-type="table"}). These two treatments together contributed to approximately 750 (13%) deaths prevented or postponed. Improved heart failure treatments contributed approximately 265 (5%) deaths prevented or postponed in community patients and 85 (2%) fewer deaths in patients admitted to hospital. Only small contributions to deaths prevented or postponed were made in the hospital based patient groups of emergency admissions for acute coronary syndromes (table 2[](#tbl2){ref-type="table"}).

###### 

 Percentage treatment uptake rates for 2000 and 2010 stratified by deprivation fifths

  Treatment by patient group                                    Scotland          Scottish Index of Multiple Deprivation fifths                                                                              
  ------------------------------------------------------------- ---------- ------ ----------------------------------------------- ------ ------ -- ------ ------ -- ------ ------ -- ------ ------ -- ------ ------
  ST elevation myocardial infarction (2500\*):                                                                                                                                                               
   Thrombolysis                                                 77.6       58.5                                                   79.7   60.5      78.0   62.1      75.9   59.4      76.3   57.4      78.7   54.5
   Aspirin                                                      93.6       96.6                                                   93.7   97.0      94.6   96.9      93.0   96.1      93.1   96.4      93.8   96.8
   β blocker                                                    71.7       72.8                                                   75.2   72.9      72.6   71.9      71.4   72.0      69.7   72.1      71.4   74.7
   ACE inhibitor or angiotensin receptor blocker                77.5       78.3                                                   79.8   78.4      79.0   77.4      75.9   77.5      75.5   77.0      78.5   80.9
   Clopidogrel                                                  28.1       90.0                                                   27.1   90.2      25.8   89.3      28.0   90.3      29.1   89.9      29.2   90.4
   Primary percutaneous coronary intervention                   4.2        58.6                                                   6.2    66.7      4.0    58.4      4.1    55.8      5.0    56.2      2.6    58.4
   Primary coronary artery bypass graft                         0.0        0.1                                                    0.0    0.3       0.2    0.0       0.0    0.0       0.0    0.2       0.0    0.0
   CPR in hospital                                              11.2       5.8                                                    9.8    5.8       11.4   6.1       11.7   5.5       11.7   5.9       11.1   5.6
   CPR in community (1315\*)                                    23.4       28.3                                                   26.6   27.8      24.2   32.4      25.8   25.3      21.1   26.4      21.5   29.5
  Non-ST elevation acute coronary syndrome (9110\*):                                                                                                                                                         
   Aspirin and heparin                                          64.0       79.9                                                   67.4   79.7      65.6   80.7      67.0   80.1      65.9   80.1      58.0   78.9
   Aspirin alone                                                24.3       12.8                                                   21.4   13.6      23.5   12.2      21.4   12.6      23.4   12.5      28.8   13.1
   Platelet glycoprotein IIB/IIIA inhibitors                    6.0        5.9                                                    9.6    6.3       7.4    6.0       6.3    5.3       4.8    5.1       4.6    7.0
   ACE inhibitor or angiotensin receptor blocker                66.2       73.5                                                   68.8   73.3      64.3   72.6      66.2   72.8      64.5   72.8      67.7   75.2
   β blocker                                                    63.9       67.9                                                   66.9   68.3      63.5   68.3      64.2   67.1      62.5   66.2      63.9   69.5
   Clopidogrel                                                  45.1       86.8                                                   44.0   87.3      44.7   87.4      43.0   87.1      46.2   86.0      46.4   86.5
   Coronary artery bypass graft surgery                         0.4        0.4                                                    0.9    0.3       0.4    0.6       0.3    0.5       0.4    0.3       0.4    0.2
   Percutaneous coronary intervention                           3.5        6.7                                                    5.6    7.9       3.1    7.8       4.2    6.2       3.3    5.9       2.6    6.4
   CPR in community                                                                                                                                                                                          
   CPR in hospital (4640\*)                                     5.2        2.4                                                    4.5    2.3       4.8    2.2       5.3    2.2       5.5    2.7       5.5    2.4
  Secondary prevention post-myocardial infarction (60 200\*):                                                                                                                                                
   Aspirin                                                      68.6       80.5                                                   67.4   80.0      69.1   78.8      67.3   78.8      69.3   80.9      69.2   83.3
   β blocker                                                    45.7       65.8                                                   50.9   67.5      45.5   63.3      47.5   64.2      44.0   65.3      43.1   68.6
   ACE inhibitor                                                26.5       68.0                                                   26.4   68.3      29.2   67.1      26.6   64.5      26.7   69.2      24.6   70.2
   Statin                                                       41.7       86.6                                                   43.4   84.9      44.2   84.6      40.9   85.7      41.6   87.0      39.8   89.5
   Warfarin                                                     4.7        6.0                                                    5.3    6.5       5.9    6.0       4.9    6.9       4.2    5.3       4.0    5.7
   Rehabilitation                                               17.1       42.1                                                   17.0   41.7      17.0   41.9      17.0   42.1      17.1   42.0      17.3   42.8
  Secondary prevention post-revascularisation (40 295):                                                                                                                                                      
   Aspirin                                                      75.6       79.2                                                   72.5   75.1      81.4   80.6      70.3   78.5      77.1   78.0      76.8   83.8
   β blocker                                                    45.3       62.0                                                   48.5   60.3      48.4   61.8      47.1   62.4      39.1   59.7      44.9   65.9
   ACE inhibitor                                                20.7       59.5                                                   21.8   56.9      22.0   53.9      16.3   60.3      24.1   65.3      19.4   60.2
   Statin                                                       62.4       90.9                                                   67.3   89.5      62.6   88.5      57.4   90.3      63.8   92.3      61.2   93.4
   Warfarin                                                     8.5        7.3                                                    6.0    8.3       6.8    7.6       11.2   8.1       9.8    7.7       8.1    5.0
   Rehabilitation (CABG) (7115\*)                               42.5       41.9                                                   43.1   41.9      42.6   42.4      42.6   41.7      42.5   42.0      42.0   41.3
   Rehabilitation (PCI) (11 100\*)                              7.5        12.4                                                   7.5    12.6      7.5    12.4      7.5    12.3      7.5    12.4      7.5    12.2
  Chronic stable coronary artery disease (72 395\*):                                                                                                                                                         
   Aspirin in community                                         59.6       73.6                                                   57.7   71.4      60.3   72.0      57.4   72.2      61.2   75.0      60.7   77.2
   Statins in community                                         28.7       78.6                                                   31.1   77.6      27.6   76.3      30.2   78.4      28.9   81.7      26.8   78.4
   ACE inhibitor                                                15.3       45.2                                                   16.8   45.2      15.7   45.1      14.6   41.7      15.7   47.9      14.8   46.4
   CABG surgery (previous 5 years)                              11.8       9.8                                                    16.0   11.9      11.9   10.5      10.2   8.6       11.4   9.9       11.4   8.8
   Heart failure in hospital (3645\*)                                                                                                                                                                        
   ACE inhibitor                                                51.4       64.3                                                   50.1   62.6      50.1   62.7      51.5   64.4      51.8   64.7      52.7   65.8
   β blocker                                                    31.9       45.6                                                   31.0   44.2      31.1   44.4      32.0   45.7      32.2   46.0      32.7   46.7
   Spironolactone                                               21.0       26.2                                                   20.5   25.6      20.3   25.4      21.1   26.4      21.2   26.6      21.2   26.5
   Aspirin                                                      71.9       79.9                                                   70.8   80.7      74.9   77.1      68.6   78.8      72.7   80.1      72.4   82.3
  Heart failure in community (16 225):                                                                                                                                                                       
   ACE inhibitor/or angiotensin receptor blocker                69.7       81.4                                                   72.6   79.7      72.5   79.4      61.5   79.3      70.0   79.7      72.7   86.5
   β blocker                                                    30.9       65.8                                                   34.3   57.3      28.2   60.0      32.8   66.9      28.2   65.5      32.1   73.3
   Spironolactone                                               7.7        11.7                                                   6.2    7.8       10.4   14.5      6.6    12.7      6.5    16.4      8.2    7.4
   Aspirin                                                      74.3       75.1                                                   71.9   75.4      71.8   76.9      71.2   71.6      77.8   73.7      77.0   77.7
  Hypertension treatment (3 685 545\*)                          12.2       18.3                                                   9.4    15.6      12.4   19.3      12.2   17.8      12.9   18.8      14.0   19.9
  Hyperlipidaemia treatment (statins) (3 685 545\*)             2.7        15.1                                                   2.2    13.2      2.8    15.8      2.8    15.3      2.6    14.3      3.2    17.0

Overall treatment uptake rate is weighted average over all age groups ≥25 years and both sexes.

ACE=angiotensin converting enzyme; CABG=coronary artery bypass graft; CPR=cardiopulmonary resuscitation; PCI=percutaneous coronary intervention.

\*Number of eligible patients, rounded to nearest 5.

The improvements due to changes in treatment uptakes were evenly distributed across deprivation fifths. The difference between the most and least deprived fifths in terms of percentage of deaths prevented or postponed was generally less than 1% for each treatment group (table 3[](#tbl3){ref-type="table"}).

Risk factor changes
-------------------

The largest contribution from population level changes in risk factors came from the 2 mm Hg fall in systolic blood pressure in people not on antihypertensive drugs; this generated approximately 2130 fewer deaths, representing 37% of the mortality decrease (table 4[](#tbl4){ref-type="table"}). In contrast, the benefits from treatment of hypertension were fairly small, with some 155 (3%) deaths averted (table 2[](#tbl2){ref-type="table"}). Socioeconomic gradients were modest; however, population level systolic blood pressure dropped during the 10 year period by 3.2 mm Hg in women and by only 0.9 mm Hg in men (table 6[](#tbl6){ref-type="table"}).

###### 

 Absolute change in risk factor levels between 2000 and 2010, stratified by deprivation fifths

  Risk factor                       Overall levels\*           Change in risk factors                                         
  --------------------------------- ------------------ ------- ------------------------ ------ -- ------ ------ ------ ------ ------
  Smoking prevalence (%):                                                                                                     
   Men                              30.3               26.0                             −4.3      −2.8   −3.5   −4.3   −4.9   −5.5
   Women                            28.9               23.7                             −5.2      −3.2   −4.0   −5.1   −5.9   −7.0
  Diabetes prevalence (%):                                                                                                    
   Men                              4.2                7.3                              3.1       2.2    3.0    3.3    3.3    3.5
   Women                            3.4                5.3                              1.9       1.2    1.3    2.1    2.1    2.6
  Physical inactivity (%):                                                                                                    
   Men                              66.3               58.9                             −7.4      −7.5   −7.3   −7.1   −7.3   −7.8
   Women                            74.6               68.4                             −6.2      −6.0   −6.2   −6.1   −6.2   −6.5
  Systolic blood pressure, mm Hg:                                                                                             
   Men                              133.1              132.2                            −0.9      −1.0   −1.0   −1.0   −0.9   −0.8
   Women                            130.1              126.9                            −3.2      −3.1   −3.1   −3.1   −3.3   −3.2
  Total cholesterol, mmol/L:                                                                                                  
   Men                              5.6                5.2                              −0.4      −0.4   −0.4   −0.4   −0.4   −0.4
   Women                            5.7                5.4                              −0.3      −0.3   −0.3   −0.3   −0.3   −0.3
  Body mass index, kg/m^2^:                                                                                                   
   Men                              27.3               28.2                             0.9       0.9    0.9    0.9    0.9    0.9
   Women                            27.1               27.9                             0.8       0.8    0.8    0.8    0.9    0.8

\*Scotland average weighted by 2010 population distribution in 10 year age bands.

The fall in cholesterol concentrations in the population not on statin treatment accounted for approximately 510 deaths averted, representing 9% of the total fall. In both absolute and relative terms, the fall in deaths attributable to cholesterol reduction in the general population was substantially higher in the most deprived fifth (170 (14%) fewer deaths) than in the most affluent fifth (43 (5%) fewer deaths). During the 10 year study period, uptake of statin treatment increased substantially, from 3% of eligible people in 2000 to 15% in 2010 (13% in the most affluent fifth and 17% in the most deprived fifth) (table 5[](#tbl5){ref-type="table"}). Cholesterol lowering by statins thus accounted for approximately 770 (13%) deaths averted, 15% in the most affluent fifth and 11% in the most deprived fifth (table 2[](#tbl2){ref-type="table"}).

Favourable trends in the behavioural risk factors made a modest contribution to deaths prevented or postponed; the drop in smoking rates contributed to approximately 210 fewer deaths or 4% (table 4[](#tbl4){ref-type="table"}). Smoking prevalence dropped by about 4% in men and 5% in women over the 10 year time period. A significant socioeconomic gradient was apparent, with approximately 14 (2%) fewer deaths evident in the most affluent fifth and some 75 (6%) fewer deaths in the most deprived fifth (table 3[](#tbl3){ref-type="table"}), reflecting larger declines in smoking prevalence. Physical inactivity declined by approximately 7% in men and 6% in women (table 6[](#tbl6){ref-type="table"}) and contributed to approximately 100 (2%) fewer deaths.

Adverse risk factor trends
--------------------------

The mortality gains from decreases in smoking and physical inactivity were cancelled out by increases in obesity and diabetes. Increases in body mass index contributed approximately 235 (−4%) additional deaths and diabetes some 475 (−8%) additional deaths (table 4[](#tbl4){ref-type="table"}). The additional deaths from diabetes showed a significant socioeconomic gradient, with 48 (−5%) more deaths in the most affluent fifth and 141 (−12%) in the most deprived fifth (table 3[](#tbl3){ref-type="table"}). This reflected a gradient in prevalence of diabetes which increased in men by 2% (1% in women) in the most affluent fifth and by 4% (3% in women) in the most deprived fifth (table 6[](#tbl6){ref-type="table"}). No significant socioeconomic gradients were associated with body mass index attributable deaths (tables 3[](#tbl3){ref-type="table"} and 4[](#tbl4){ref-type="table"}).

Discussion
==========

Coronary heart disease remains a top policy priority in Scotland. CHD mortality fell by more than 40% between 2000 and 2010, resulting in approximately 5770 fewer deaths. The largest contributors to this decline were favourable population level falls in blood pressure and serum cholesterol concentrations. However, we found evidence of unfavourable trends in body mass index and diabetes that threaten to reverse these trends. The falls in mortality were steeper in the more affluent groups, so relative inequalities remained fairly constant. These differentials are likely to reflect inequalities in risk factor trends, rather than in evidence based treatments (which were remarkably equitable).

Reductions in cardiovascular risk factor levels explained approximately two fifths of the fall in CHD mortality. The single largest contribution came from secular falls in population blood pressure. Furthermore, blood pressure falls were of a similar magnitude across socioeconomic groups. This is consistent with the encouraging population-wide reductions in dietary salt consumption seen in Scotland and England.[@ref13] [@ref23] The greater fall in blood pressure in women than in men resulted in a correspondingly larger contribution to the CHD deaths prevented. The underlying contributory factors therefore represent a possible area for future investigation. As elsewhere, the mortality benefit from hypertension treatments was relatively small.

Favourable trends in smoking and physical activity made only a modest contribution to the falls in mortality. However, the reductions in deaths due to smoking were greater in the deprived groups, mirroring the larger declines in smoking prevalence. This may reflect the benefits of smoke-free legislation introduced in Scotland in 2006.[@ref24] However, smoking remains prevalent in deprived areas and substantial inequalities persist, representing a government policy priority.[@ref25] [@ref26]

Modest mortality benefits were also attributable to population declines in cholesterol concentrations in people not on statin treatment, again greater in deprived groups. These benefits may reflect modest decreases in dietary saturated fat consumption and increases in fruit and vegetable consumption. However, the small benefits were notably less than for statin treatment. Furthermore, the Scottish government's dietary targets were not met,[@ref27] leaving little room for complacency.

Adverse trends
--------------

Falls in major cardiovascular risk factor levels explained approximately 40% of the fall in CHD mortality. However, the net benefit was substantially reduced by increasing levels of obesity and diabetes, which together increased mortality by 12% (\>700 additional deaths). Increasing prevalence of diabetes showed a strong socioeconomic gradient whereby surplus deaths were almost three times higher in the most deprived group than the most affluent. This represents a clarion call to policy makers.[@ref28]

Treatment contributions
-----------------------

Approximately 40% of the total fall in CHD mortality was attributable to improvements in the uptake of treatments, notably a doubling in drug use in the community. Medical interventions in hospital settings made only a small additional contribution because CHD incidence rates are declining with fewer patients therefore being admitted to hospital with acute disease, treatment uptakes were already high (hence with little margin for further increases), and few new treatments were introduced during the study period.

Although the CHD disease burden showed strong socioeconomic gradients, the improvements in mortality due to changes in treatment uptake were fairly evenly distributed across deprivation fifths. This is gratifying and suggests an equitable delivery of CHD care by the Scottish NHS. Subjectively, sex equality also existed in the delivery of care, although this requires further formal investigation.

Comparison with England IMPACT~SEC~model
----------------------------------------

Our analysis is only the second IMPACT~SEC~ study to examine socioeconomic trends in CHD mortality. It thus begs comparison with the first, which modelled similar English data between 2000 and 2007.[@ref12]

As expected, many similarities exist, including substantial and persistent socioeconomic inequalities in CHD death rates and smoking levels. Overall mortality falls were equally large, and in both cases a third was attributable to changes in risk factors. The biggest contribution to the fall in mortality was consistently attributed to declines in population blood pressure (37% in Scotland and 30% in England), partly reflecting reductions in dietary salt. In both countries, worrying adverse trends in body mass index and diabetes equated to substantial rises in coronary mortality (12% in Scotland; 9% in England).

The Scottish model attributed approximately 40% of the total fall in CHD mortality to improved uptakes of medical treatments, compared with 50% in England. Importantly, both models showed equitable reductions in mortality attributable to treatments across socioeconomic groups, most likely reflecting the uniform health service provision for CHD treatments.

Strengths and limitations
-------------------------

This is the first study to use local datasets to quantify detailed contributions of changes in treatment and risk factors to falls in coronary mortality within socioeconomic groups in Scotland. It is only the second IMPACT study to examine socioeconomic variations. Scotland benefits from having the only UK morbidity databases that routinely link all hospital admission information with all mortality data. This should generate accurate estimates of various patient groups, incidence, and case fatality stratified by age, sex, and, where numbers are large enough, deprivation. This minimised the assumptions that had to be made regarding overlap between disease groups by ensuring that people could be included in only one group. Some data were difficult to access, perhaps reflecting insufficient resources to sustain diverse audit projects.

Several limitations should also be acknowledged. Firstly, the routine data used in this study permitted stratification by an area based measure of deprivation, but not by individual person. However, such small area indices offer reasonably effective markers of personal social status.[@ref29]

Secondly, mortality rates are dependent on population estimates. Because population estimates from the 2011 census were not yet available, the small area population estimates by data zone needed for our Scottish Index of Multiple Deprivation stratified analysis were based on the 2000 census with populations rolled forward to 2010.[@ref30] Clearly, small areas may change over time with regards to population size, demographic characteristics, and socioeconomic make-up, so estimates of mortality rates may be less stable in 2010.

Thirdly, our model could not explain 18% of the overall decline in CHD mortality; uncertainty analyses would suggest that this figure could be as little as 1% or as much as 35%. Several possible explanations exist for this shortfall. Firstly, risk factor estimates obtained from the Scottish Health Survey may lack precision owing to small numbers, compounded by self reporting of smoking and inactivity levels and declining survey response rates.[@ref31] Secondly, other risk factors such as psychosocial stress and dietary consumption of fruit and vegetables, saturated fat, or alcohol were omitted from our model. However, the effect of these "upstream" factors should be partly quantified by trends in "downstream" factors (blood pressure, cholesterol, body mass index, and diabetes).[@ref32] Furthermore, the consistent results from the rigorous sensitivity analyses were reassuring.

Policy implications
-------------------

The substantial decline in CHD mortality over the past decade in Scotland can be attributed fairly equally to increased medical treatments and to improvements in risk factors. However, the potentially powerful reductions in smoking and cholesterol were frustratingly small and were completely negated by large adverse trends in obesity and diabetes. Scotland's past tobacco and dietary policies deserve credit.[@ref25] [@ref26] However, more effective public health policies exist elsewhere and have substantially and equitably reduced the intake of saturated fats, trans fats, salt, and sugars.[@ref28] [@ref33] [@ref34] Likewise, proposed standard packaging legislation,[@ref26] if implemented, could lower smoking in all socioeconomic groups and thus reduce CHD mortality across Scotland.

### What is already known on this topic

1.  In spite of recent falls in mortality, coronary heart disease (CHD) remains the largest cause of death in Scotland and generates strong and persistent socioeconomic inequalities

2.  Smoking prevalence in Scotland has fallen, but absolute levels remain high

3.  Worryingly, other cardiovascular risk factors such as obesity and diabetes have recently increased

### What this study adds

1.  CHD mortality in Scotland fell by 43% between 2000 and 2010; the single largest contribution came from population level falls in blood pressure

2.  The contribution from improvements in smoking and cholesterol concentrations was frustratingly small and was completely negated by increases in obesity and diabetes

3.  The CHD burden showed strong socioeconomic gradients; however, the mortality reductions attributable to improved treatment uptakes were evenly distributed across socioeconomic fifths, suggesting an equitable delivery of care by the Scottish NHS
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